TSHA-102 remains well tolerated with no severe adverse events in Rett syndrome trial, Taysha Gene Therapies reveals

TSHA-102 remains well tolerated with no severe adverse events in Rett syndrome trial, Taysha Gene Therapies reveals
Taysha Q3 earnings and TSHA-102 update

Taysha Gene Therapies released its third quarter earnings, providing an updated snapshot of the company’s financial status and ongoing initiatives.

The company reported that its lead gene therapy candidate, TSHA-102, currently under clinical evaluation for Rett syndrome, continues to exhibit a favorable safety profile. According to Taysha Gene Therapies, TSHA-102 remains generally well tolerated, with no severe treatment-related serious adverse events observed to date.

Earlier this year, Taysha Gene Therapies presented new clinical progress on TSHA-102 for Rett syndrome at a key neurology meeting, as reported in a previous update. The company also discussed TSHA-102 advancements with the neurology community at the CNSAM event, according to company disclosures. These activities have focused attention on the development of TSHA-102 in the clinical setting.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.